ReviewFrontiers in medicine2025
Research progress on the diagnostic value of fecal calprotectin in colorectal tumors.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Cytokine Profiles Associated with Inflammation and Tumor Progression in Crohn's Disease and Colorectal Cancer.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fecal Calprotectin (FC), a calcium-binding protein secreted by neutrophils and macrophages and belonging to the S100 protein family, has gained increasing utilization in recent years for the diagnosis and monitoring of intestinal diseases due to its high expression and stability in inflammatory responses. In the field of colorectal tumors, the diagnostic value of FC has gradually emerged. Within colorectal tumors, colorectal cancer (CRC) is an area of significant research focus. Studies have demonstrated significantly elevated FC levels in patients with CRC, a phenomenon potentially linked to chronic inflammation and immune cell infiltration within the tumor microenvironment. FC exhibits notable advantages in colorectal tumor diagnosis, characterized by high sensitivity and moderate specificity. Emerging research has revealed correlations between FC levels and colorectal tumors staging as well as left-sided versus right-sided tumor localization, with elevated FC levels associated with malignant transformation, local inflammation, and advanced tumor stages (T3 and T4). The diagnostic performance of fecal calprotectin (FC) as a non-invasive marker for colorectal tumors has not yet been established. However, due to its association with inflammation, FC holds promise for playing a more significant role in the screening, staging, and localization of colorectal tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.